Helene Verdoux

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8592924/publications.pdf

Version: 2024-02-01

224 papers

11,066 citations

³⁸⁷²⁰ 50 h-index

97 g-index

271 all docs

271 docs citations

times ranked

271

9428 citing authors

#	Article	IF	CITATIONS
1	Evidence that three dimensions of psychosis have a distribution in the general population. Psychological Medicine, 2002, 32, 347-358.	2.7	772
2	Cannabis Use and Psychosis: A Longitudinal Population-based Study. American Journal of Epidemiology, 2002, 156, 319-327.	1.6	746
3	Psychotic symptoms in non-clinical populations and the continuum of psychosis. Schizophrenia Research, 2002, 54, 59-65.	1.1	463
4	Benzodiazepine use and risk of Alzheimer's disease: case-control study. BMJ, The, 2014, 349, g5205-g5205.	3.0	407
5	Obstetric complications and age at onset in schizophrenia: an international collaborative meta-analysis of individual patient data. American Journal of Psychiatry, 1997, 154, 1220-1227.	4.0	337
6	Benzodiazepine use and risk of dementia: prospective population based study. BMJ, The, 2012, 345, e6231-e6231.	3.0	323
7	Schizophrenia and Complications of Pregnancy and Labor: An Individual Patient Data Meta-analysis. Schizophrenia Bulletin, 1999, 25, 413-423.	2.3	289
8	Women with anxiety disorders during pregnancy are at increased risk of intense postnatal depressive symptoms: a prospective survey of the MATQUID cohort. European Psychiatry, 2004, 19, 459-463.	0.1	229
9	Antipsychotic prescribing trends: a review of pharmacoâ€epidemiological studies. Acta Psychiatrica Scandinavica, 2010, 121, 4-10.	2.2	215
10	A survey of delusional ideation in primary-care patients. Psychological Medicine, 1998, 28, 127-134.	2.7	192
11	International trends in clozapine use: a study in 17 countries. Acta Psychiatrica Scandinavica, 2017, 136, 37-51.	2.2	188
12	International trends in antipsychotic use: A study in 16 countries, 2005–2014. European Neuropsychopharmacology, 2017, 27, 1064-1076.	0.3	185
13	Effects of cannabis and psychosis vulnerability in daily life: an experience sampling test study. Psychological Medicine, 2003, 33, 23-32.	2.7	184
14	Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects. Acta Psychiatrica Scandinavica, 2000, 102, 203-210.	2.2	179
15	Is early adulthood a critical developmental stage for psychosis proneness? A survey of delusional ideation in normal subjects. Schizophrenia Research, 1998, 29, 247-254.	1.1	168
16	Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. International Clinical Psychopharmacology, 2005, 20, 131-137.	0.9	165
17	Maternal depressive symptoms and early childhood cognitive development: a meta-analysis. Psychological Medicine, 2017, 47, 680-689.	2.7	154
18	Self-reported psychosis-like symptoms and the continuum of psychosis. Social Psychiatry and Psychiatric Epidemiology, 1999, 34, 459-463.	1.6	146

#	Article	IF	Citations
19	How psychotic are individuals with non-psychotic disorders?. Social Psychiatry and Psychiatric Epidemiology, 2003, 38, 149-154.	1.6	146
20	Patterns and correlates of benzodiazepine use in the French general population. European Journal of Clinical Pharmacology, 2004, 60, 523-529.	0.8	138
21	Is the association between duration of untreated psychosis and outcome confounded? A two year follow-up study of first-admitted patients. Schizophrenia Research, 2001, 49, 231-241.	1.1	135
22	Cognitive predictors of psychosocial functioning outcome in schizophrenia: A follow-up study of subjects participating in a rehabilitation program. Schizophrenia Research, 2005, 77, 343-353.	1.1	119
23	Psychotropic drugs use and risk of heat-related hospitalisation. European Psychiatry, 2007, 22, 335-338.	0.1	119
24	A comparative study of obstetric history in schizophrenics, bipolar patients and normal subjects. Schizophrenia Research, 1993, 9, 67-69.	1.1	109
25	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. Pharmacopsychiatry, 2022, 55, 73-86.	1.7	107
26	Is benzodiazepine use a risk factor for cognitive decline and dementia? A literature review of epidemiological studies. Psychological Medicine, 2005, 35, 307-315.	2.7	102
27	Consensus statement on the use of clozapine during the COVID-19 pandemic. Journal of Psychiatry and Neuroscience, 2020, 45, 222-223.	1.4	102
28	Increased occurrence of depression in psychosis-prone subjects: A follow-up study in primary care settings. Comprehensive Psychiatry, 1999, 40, 462-468.	1.5	97
29	Cannabis use and anxiety in daily life: a naturalistic investigation in a non-clinical population. Psychiatry Research, 2003, 118, 1-8.	1.7	97
30	Cannabis use and dimensions of psychosis in a nonclinical population of female subjects. Schizophrenia Research, 2003, 59, 77-84.	1.1	95
31	Predictors and outcome characteristics associated with suicidal behaviour in early psychosis: a two-year follow-up of first-admitted subjects. Acta Psychiatrica Scandinavica, 2001, 103, 347-354.	2.2	94
32	Schizophrenia: who is at risk? Who is a case?. International Clinical Psychopharmacology, 2006, 21, S17-S19.	0.9	90
33	A prospective longitudinal study of the impact of early postnatal vs. chronic maternal depressive symptoms on child development. European Psychiatry, 2011, 26, 484-489.	0.1	87
34	Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS). Schizophrenia Research, 2012, 134, 187-194.	1.1	87
35	Substance use and the course of early psychosis: a 2-year follow-up of first-admitted subjects. European Psychiatry, 2003, 18, 133-136.	0.1	85
36	Does Familiality Predispose to both Emergence and Persistence of Psychosis?. British Journal of Psychiatry, 1996, 168, 620-626.	1.7	81

#	Article	IF	CITATIONS
37	Atypical Antipsychotics. Drug Safety, 2005, 28, 35-51.	1.4	81
38	Prescriber and institutional barriers and facilitators of clozapine use: A systematic review. Schizophrenia Research, 2018, 201, 10-19.	1.1	80
39	Self-assessed cognitive dysfunction and objective performance in outpatients with schizophrenia participating in a rehabilitation program. Schizophrenia Research, 2004, 69, 85-91.	1.1	79
40	Neuroleptic effects on neuropsychological test performance in schizophrenia. Schizophrenia Research, 1995, 14, 133-139.	1.1	74
41	Which temperamental characteristics are associated with substance use in subjects with psychotic and mood disorders?. Psychiatry Research, 2000, 93, 63-72.	1.7	73
42	Specific vs general cognitive remediation for executive functioning in schizophrenia: A multicenter randomized trial. Schizophrenia Research, 2013, 147, 68-74.	1.1	72
43	Suicidality and substance misuse in first-admitted subjects with psychotic disorder. Acta Psychiatrica Scandinavica, 2007, 100, 389-395.	2.2	69
44	Prediction of duration of psychosis before first admission. European Psychiatry, 1998, 13, 346-352.	0.1	68
45	Neuropsychological function in subjects with psychotic and affective disorders. Relationship to diagnostic category and duration of illness. European Psychiatry, 2000, 15, 236-243.	0.1	67
46	Social and clinical consequences of cognitive deficits in early psychosis: a two-year follow-up study of first-admitted patients. Schizophrenia Research, 2002, 56, 149-159.	1.1	66
47	Evolution of perinatal depressive symptoms from pregnancy to two years postpartum in a low-risk sample: The MATQUID cohort. Journal of Affective Disorders, 2012, 139, 23-29.	2.0	65
48	Neuroleptics and mortality in schizophrenia: prospective analysis of deaths in a French cohort of schizophrenic patients. Schizophrenia Research, 2002, 57, 147-156.	1.1	63
49	Obstetrical complications and the development of postpartum depressive symptoms: a prospective survey of the MATQUID cohort. Acta Psychiatrica Scandinavica, 2002, 106, 212-219.	2.2	62
50	Agreement Between Self-Rated and Clinically Assessed Symptoms in Subjects With Psychosis. Journal of Nervous and Mental Disease, 2004, 192, 352-356.	0.5	61
51	Psychotic Experiences and Related Distress: A Cross-national Comparison and Network Analysis Based on 7141 Participants From 13 Countries. Schizophrenia Bulletin, 2018, 44, 1185-1194.	2.3	54
52	Temperament in bipolar illness: impact on prognosis. Journal of Affective Disorders, 1999, 56, 103-108.	2.0	53
53	Clinical determinants of fever in clozapine users and implications for treatment management: A narrative review. Schizophrenia Research, 2019, 211, 1-9.	1.1	52
54	Perinatal risk factors for schizophrenia: Diagnostic specificity and relationships with maternal psychopathology. American Journal of Medical Genetics Part A, 2002, 114, 898-905.	2.4	51

#	Article	IF	CITATIONS
55	Pathways to care of first-admitted subjects with psychosis in South-Western France. Psychological Medicine, 2004, 34, 267-276.	2.7	51
56	Clozapine is strongly associated with the risk of pneumonia and inflammation. Annals of General Psychiatry, 2020, 33, e100183.	1.1	50
57	The current state of adult mental health care in France. European Archives of Psychiatry and Clinical Neuroscience, 2007, 257, 64-70.	1.8	45
58	Prenatal Psychological Distress and Access to Mental Health Care in the ELFE Cohort. European Psychiatry, 2015, 30, 322-328.	0.1	45
59	Impact of substance use on the onset and course of early psychosis. Schizophrenia Research, 2005, 79, 69-75.	1.1	43
60	Factors influencing compulsory admission in first-admitted subjects with psychosis. Social Psychiatry and Psychiatric Epidemiology, 2004, 39, 804-809.	1.6	41
61	Delusional Parasitosis: Folie à Deux and Attempted Murder of a Family Doctor. British Journal of Psychiatry, 1992, 161, 709-711.	1.7	40
62	The crucial role of sustained attention in community functioning in outpatients with schizophrenia. Psychiatry Research, 2004, 129, 171-177.	1.7	40
63	Trends in incident use of benzodiazepines and Z-drugs in France from 2006 to 2012: a population-based study. Pharmacoepidemiology and Drug Safety, 2017, 26, 162-169.	0.9	40
64	Perinatal risk factors for schizophrenia: How specific are they?. Current Psychiatry Reports, 2004, 6, 162-167.	2.1	38
65	A survey of prescribing practice of antipsychotic maintenance treatment for manic-depressive outpatients. Journal of Affective Disorders, 1996, 38, 81-87.	2.0	37
66	Focus on psychiatry in France. British Journal of Psychiatry, 2003, 183, 466-471.	1.7	37
67	Comorbidities and concurrent medications increasing the risk of adverse drug reactions: prevalence in French benzodiazepine users. European Journal of Clinical Pharmacology, 2016, 72, 869-876.	0.8	37
68	Is the intensity of Schneiderian symptoms related to handedness and speech disorder in subjects with psychosis?. Schizophrenia Research, 2004, 67, 167-173.	1.1	36
69	General Practitioners' Choices and Their Determinants When Starting Treatment for Major Depression: A Cross Sectional, Randomized Case-Vignette Survey. PLoS ONE, 2012, 7, e52429.	1.1	36
70	Pharmaco-epidemiology: What do (and don't) we know about utilisation and impact of psychotropic medications in real-life conditions?. British Journal of Psychiatry, 2004, 185, 93-94.	1.7	34
71	Risk of Death Related to Psychotropic Drug Use in Older People During the European 2003 Heatwave: A Population-Based Case–Control Study. American Journal of Geriatric Psychiatry, 2009, 17, 1059-1067.	0.6	34
72	Antidepressants and Hepatotoxicity: A Cohort Study among 5 Million Individuals Registered in the French National Health Insurance Database. CNS Drugs, 2018, 32, 673-684.	2.7	32

#	Article	lF	Citations
73	The 4-Point ordinal Alliance Self-report: a self-report questionnaire for assessing therapeutic relationships in routine mental health. Comprehensive Psychiatry, 2009, 50, 181-185.	1.5	31
74	Antipsychotic prescribing in youths: a French community-based study from 2006 to 2013. European Child and Adolescent Psychiatry, 2015, 24, 1181-1191.	2.8	31
75	Seasonality of birth in schizophrenia: the effect of regional population density. Schizophrenia Research, 1997, 23, 175-180.	1.1	30
76	Association between temperamental characteristics and medication adherence in subjects presenting with psychotic or mood disorders. Psychiatry Research, 2001, 102, 91-95.	1.7	30
77	Newborn Behavior and Risk of Postnatal Depression in the Mother. Infancy, 2003, 4, 589-602.	0.9	30
78	Social environments and daily life occurrence of psychotic symptoms. Social Psychiatry and Psychiatric Epidemiology, 2003, 38, 654-661.	1.6	30
79	An update on the complex relationship between clozapine and pneumonia. Expert Review of Clinical Pharmacology, 2021, 14, 145-149.	1.3	30
80	Life-threatening adverse drug reactions at admission to medical intensive care: aÂprospective study in aÂteaching hospital. Intensive Care Medicine, 2007, 33, 2150-2157.	3.9	29
81	Impact of Prenatal Exposure to Psychotropic Drugs on Neonatal Outcome in Infants of Mothers With Serious Psychiatric Illnesses. Journal of Clinical Psychiatry, 2015, 76, 967-973.	1.1	28
82	How to improve recognition and diagnosis of depressive syndromes using international diagnostic criteria. British Journal of General Practice, 1998, 48, 1245-6.	0.7	28
83	Post-partum blues and mild depressive symptomatology at days three and five after delivery. Journal of Affective Disorders, 1997, 44, 1-4.	2.0	27
84	The early detection and treatment controversy in schizophrenia research. Current Opinion in Psychiatry, 2003, 16, 175-179.	3.1	26
85	Physicians' Characteristics Associated with Exploring Suicide Risk among Patients with Depression: A French Panel Survey of General Practitioners. PLoS ONE, 2013, 8, e80797.	1.1	26
86	Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder. International Clinical Psychopharmacology, 2007, 22, 107-115.	0.9	25
87	Impact of antidepressants on the risk of suicide in patients with depression in real-life conditions: a decision analysis model. Psychological Medicine, 2009, 39, 1307-1315.	2.7	25
88	Factors associated with choice of psychotropic drugs used for intentional drug overdose. European Archives of Psychiatry and Clinical Neuroscience, 2009, 259, 86-91.	1.8	25
89	Antipsychotic long-acting injections: A community-based study from 2007 to 2014 of prescribing trends and characteristics associated with initiation. Schizophrenia Research, 2016, 178, 58-63.	1.1	25
90	Comparison of pharmacy-based and diagnosis-based comorbidity measures from medical administrative data. Pharmacoepidemiology and Drug Safety, 2017, 26, 402-411.	0.9	24

#	Article	IF	Citations
91	Frequency and pattern of Internet use in patients with schizophrenia or bipolar disorders seeking medical information. Psychiatry Research, 2017, 247, 152-154.	1.7	24
92	Satisfaction and Needs in Serious Mental Illness and Autism Spectrum Disorder: The REHABase Psychosocial Rehabilitation Project. Psychiatric Services, 2019, 70, 316-323.	1.1	24
93	Patterns of risperidone prescription: a utilization study in south-west France. Acta Psychiatrica Scandinavica, 2004, 109, 202-206.	2.2	23
94	Risk of discontinuation of antipsychotic longâ€acting injections vs. oral antipsychotics in realâ€life prescribing practice: a communityâ€based study. Acta Psychiatrica Scandinavica, 2017, 135, 429-438.	2.2	23
95	Self-stigma in serious mental illness and autism spectrum disorder: Results from the REHABase national psychiatric rehabilitation cohort. European Psychiatry, 2020, 63, e13.	0.1	23
96	Cannabis use and risk of psychosis: an etiological link?. Epidemiologia E Psichiatria Sociale, 2004, 13, 113-119.	1.0	22
97	How do general practitioners manage subjects with early schizophrenia and collaborate with mental health professionals?. Social Psychiatry and Psychiatric Epidemiology, 2005, 40, 892-898.	1.6	22
98	Social inequalities in new antidepressant treatment: a study at the individual and neighborhood levels. Annals of Epidemiology, 2013, 23, 99-105.	0.9	22
99	Have the times come for early intervention in psychosis?. Acta Psychiatrica Scandinavica, 2001, 103, 321-322.	2.2	21
100	Pattern of health service utilization and predictors of readmission after a first admission for psychosis: a 2-year follow-up study. Acta Psychiatrica Scandinavica, 2006, 113, 340-349.	2,2	21
101	Self-perceived cognitive deficits and occupational outcome in persons with schizophrenia. Psychiatry Research, 2010, 178, 437-439.	1.7	21
102	Diagnosis and classification of schizophrenia: categories versus dimensions, distributions versus disease., 2002,, 364-410.		19
103	Time Between Schizophrenia Onset and First Request for Disability Status in France and Associated Patient Characteristics. Psychiatric Services, 2007, 58, 1427-1432.	1.1	19
104	Impact of Duration of Antidepressant Treatment on the Risk of Occurrence of a New Sequence of Antidepressant Treatment. Pharmacopsychiatry, 2011, 44, 96-101.	1.7	19
105	Geographical disparities in prescription practices of lithium and clozapine: a communityâ€based study. Acta Psychiatrica Scandinavica, 2016, 133, 470-480.	2.2	19
106	Effects of depression and cognitive impairment on quality of life in older adults with schizophrenia spectrum disorder: Results from a multicenter study. Journal of Affective Disorders, 2019, 256, 164-175.	2.0	19
107	Psychotic disorders among homeless subjects attending a psychiatric emergency service. Social Psychiatry and Psychiatric Epidemiology, 2006, 41, 904-910.	1.6	18
108	Congruence between diagnosis of recurrent major depressive disorder and psychotropic treatment in the general population. Acta Psychiatrica Scandinavica, 2007, 117, 071028185208001-???.	2.2	18

7

#	Article	IF	Citations
109	Social Inequalities in Early Antidepressant Discontinuation. Psychiatric Services, 2014, 65, 618-625.	1.1	18
110	Psychosis as an Extreme of Continuous Variation in Dimensions of Psychopathology., 1999,, 59-79.		18
111	A Case of Lithium Neurotoxicity with Irreversible Cerebellar Syndrome. Journal of Nervous and Mental Disease, 1990, 178, 761-762.	0.5	17
112	A One-Day Survey of Characteristics of Off-Label Hospital Prescription of Psychotropic Drugs. Pharmacopsychiatry, 2007, 40, 116-120.	1.7	17
113	Dealing with missing data in the Center for Epidemiologic Studies Depression self-report scale: a study based on the French E3N cohort. BMC Medical Research Methodology, 2013, 13, 28.	1.4	17
114	Clozapine use pattern in persons with and without treatment for Parkinson's disease in real-world conditions: a naturalistic study in a community-based sample. Acta Psychiatrica Scandinavica, 2014, 130, 487-497.	2,2	17
115	A decision analysis model to assess the feasibility of the early detection of psychosis in the general population. Schizophrenia Research, 2005, 74, 27-36.	1.1	16
116	Psychotherapy for depression in primary care: a panel survey of general practitioners' opinion and prescribing practice. Social Psychiatry and Psychiatric Epidemiology, 2014, 49, 59-68.	1.6	16
117	Comparing psychotic experiences in low-and-middle-income-countries and high-income-countries with a focus on measurement invariance. Psychological Medicine, 2022, 52, 1509-1516.	2.7	16
118	Characteristics associated with self-reported medication adherence in persons with psychosis referred to psychosocial rehabilitation centers. European Archives of Psychiatry and Clinical Neuroscience, 2020, 271, 1415-1424.	1.8	16
119	A comparison of manic patient subgroups. Journal of Affective Disorders, 1993, 27, 267-272.	2.0	15
120	Social class in unipolar and bipolar probands and relatives. Journal of Affective Disorders, 1995, 33, 181-187.	2.0	15
121	Serious psychiatric outcome of subjects prenatally exposed to diethylstilboestrol in the E3N cohort study. Psychological Medicine, 2007, 37, 1315-1322.	2.7	15
122	Characteristics Associated With Use of Homeopathic Drugs for Psychiatric Symptoms in the General Population. European Psychiatry, 2013, 28, 110-116.	0.1	15
123	Assessing Metacognition during a Cognitive Task: Impact of "On-line―Metacognitive Questions on Neuropsychological Performances in a Non-clinical Sample. Journal of the International Neuropsychological Society, 2014, 20, 547-554.	1.2	15
124	Associations between self-esteem, anxiety and depression and metacognitive awareness or metacognitive knowledge. Psychiatry Research, 2015, 230, 738-741.	1.7	15
125	Psychotropic drug dispensing in people with and without cancer in France. Journal of Cancer Survivorship, 2017, 11, 92-101.	1.5	15
126	Trajectory analysis of anxiolytic dispensing over 10 years among new users aged 50 and older. Acta Psychiatrica Scandinavica, 2018, 137, 328-341.	2.2	15

#	Article	lF	Citations
127	GPs' management of polypharmacy and therapeutic dilemma in patients with multimorbidity: a cross-sectional survey of GPs in France. British Journal of General Practice, 2019, 69, e270-e278.	0.7	15
128	Comparison of Patient Questionnaires and Plasma Assays in Intentional Drug Overdoses. Basic and Clinical Pharmacology and Toxicology, 2004, 95, 31-37.	1.2	14
129	Antidepressant treatment patterns in younger and older adults from the general population in a real-life setting. International Journal of Geriatric Psychiatry, 2014, 29, 928-935.	1.3	14
130	Conventional mood stabilizers and/or second-generation antipsychotic drugs in bipolar disorders: A population-based comparison of risk of treatment failure. Journal of Affective Disorders, 2019, 257, 412-420.	2.0	14
131	Psychiatric and physical outcomes of long-term use of lithium in older adults with bipolar disorder and major depressive disorder: A cross-sectional multicenter study. Journal of Affective Disorders, 2019, 259, 210-217.	2.0	14
132	Cannabis use and the expression of psychosis vulnerability in daily life. European Psychiatry, 2002, 17, 180.	0.1	13
133	Cannabis and psychosis proneness. , 2004, , 75-88.		13
134	Compliance of psychotropic drug prescription with clinical practice guidelines in older inpatients. Fundamental and Clinical Pharmacology, 2016, 30, 82-92.	1.0	13
135	A Partial Form of Lycanthropy with Hair Delusion in a Manic-Depressive Patient. British Journal of Psychiatry, 1993, 163, 684-686.	1.7	12
136	Psychiatric disorders and their comorbidity in subjects with parasuicide by intentional drug overdose: Prevalence and gender differences. Psychiatry Research, 2005, 136, 93-100.	1.7	12
137	A survey of general practitioners' knowledge of symptoms and epidemiology of schizophrenia. European Psychiatry, 2006, 21, 238-244.	0.1	12
138	The Prognostic Impact of Psychotropic Drugs in Intentional Drug Overdose. Pharmacopsychiatry, 2009, 42, 51-56.	1.7	12
139	Eight-Year Follow-up of Hypnotic Delivery by Adults Aged 50 and Older from an Insurance Database. Sleep, 2017, 40, .	0.6	12
140	Analysis of the seasonal variation of schizophrenic births using a Kolmogorov-Smirnov type statistic. European Psychiatry, 1997, 12, 111-116.	0.1	11
141	Cognitive Insight in Schizophrenia. Journal of Nervous and Mental Disease, 2012, 200, 908-910.	0.5	11
142	Misuse of benzodiazepines: Prevalence and impact in an inpatient population with psychiatric disorders. British Journal of Clinical Pharmacology, 2020, 86, 601-610.	1.1	11
143	Antidepressants: psychiatrists' opinions and clinical practice. Acta Psychiatrica Scandinavica, 2003, 108, 24-31.	2.2	10
144	Accuracy of information on substance use recorded in medical charts of patients with intentional drug overdose. Psychiatry Research, 2007, 152, 73-79.	1.7	10

#	Article	IF	Citations
145	Pharmacoepidemiology of psychotropic drugs: examples of current research challenges on major public health issues. Epidemiologia E Psichiatria Sociale, 2009, 18, 107-113.	1.0	10
146	Trends in patterns of antidepressant use in older general population between 2006 and 2012 following publication of practice guidelines. International Journal of Geriatric Psychiatry, 2017, 32, 849-859.	1.3	10
147	Stigma resistance is associated with advanced stages of personal recovery in serious mental illness patients enrolled in psychiatric rehabilitation. Psychological Medicine, 2022, 52, 2155-2165.	2.7	10
148	EducationalÂneeds and psychoeducation interventions in clozapine users: a narrative review. Acta Psychiatrica Scandinavica, 2020, 142, 96-108.	2.2	10
149	5. Les relations entre cognition et handicap psychique dans la schizophrénie. , 2011, , 135-159.		10
150	Accuracy of self-report and toxicological assays to detect substance misuse disorders in parasuicide patients. Acta Psychiatrica Scandinavica, 2003, 108, 410-418.	2.2	9
151	Characteristics associated with duration of employment of persons with schizophrenia after first contact with psychiatric services. Work, 2009, 34, 365-371.	0.6	9
152	Economic impact of antidepressant treatment duration in naturalistic conditions. Acta Psychiatrica Scandinavica, 2013, 127, 365-372.	2.2	9
153	Impact of anticholinergic load on functioning and cognitive performances of persons with psychosis referred to psychosocial rehabilitation centers. Psychological Medicine, 2021, 51, 2789-2797.	2.7	9
154	The risk of dementia in patients using psychotropic drugs: Antidepressants, mood stabilizers or antipsychotics. Acta Psychiatrica Scandinavica, 2022, 145, 56-66.	2.2	9
155	Early detection of schizophrenia. British Journal of Psychiatry, 1997, 170, 579-579.	1.7	8
156	Implementing early intervention in psychosis Acta Psychiatrica Scandinavica, 2003, 107, 79-79.	2.2	8
157	Influence of the drug exposure definition on the assessment of the antipsychotic metabolic impact in patients initially treated with moodâ€stabilizers. British Journal of Clinical Pharmacology, 2012, 74, 189-196.	1.1	8
158	Trial exclusion criteria and their impact on the estimation of antipsychotic drugs effect: A case study using the SOHO database. Schizophrenia Research, 2018, 193, 146-153.	1.1	8
159	Efficiency and safety of oxcarbazepine in mood disorders: A naturalistic study exploring the interest of plasma dosages. European Psychiatry, 2008, 23, 409-412.	0.1	7
160	Antipsychotic use Patterns in Persons Initially Treated with Mood Stabilizers: A Naturalistic Study. Pharmacopsychiatry, 2010, 43, 17-23.	1.7	7
161	Depression and Severe Heart Failure: Benefits of Cardiac Resynchronization Therapy. Journal of Cardiovascular Electrophysiology, 2012, 23, 631-636.	0.8	7
162	Multiâ€trajectories of antidepressant and antipsychotic use: a 11â€year naturalistic study in a communityâ€based sample. Acta Psychiatrica Scandinavica, 2019, 139, 536-547.	2.2	7

#	Article	IF	Citations
163	Assessing metacognition during or after basic-level and high-level cognitive tasks? A comparative study in a non-clinical sample. L'Encephale, 2020, 46, 3-6.	0.3	7
164	A reappraisal of the role of fever in the occurrence of neurological sequelae following lithium intoxication: a systematic review. Expert Opinion on Drug Safety, 2021, 20, 827-838.	1.0	7
165	A decade of debate on early intervention in psychosis: a systematic review of screening criteria. Schizophrenia Research, 2003, 60, 91-93.	1.1	6
166	Impact of visits from pharmaceutical company representatives on antipsychotic prescription in primary care. Schizophrenia Research, 2005, 77, 107-109.	1.1	6
167	The central role of self-esteem in the quality of life of patients with mental disorders. Scientific Reports, 2022, 12, 7852.	1.6	6
168	Research activities on schizophrenia in 17 non-english speaking countries: a MEDLINE survey. European Psychiatry, 1997, 12, 319-320.	0.1	5
169	Prognostic impact of psychoactive substances use during hospitalization for intentional drug overdose. Acta Psychiatrica Scandinavica, 2005, 112, 134-140.	2.2	5
170	Trends in costs of antipsychotics in France. European Psychiatry, 2009, 24, 214-215.	0.1	5
171	Transition in care in persons with antidepressant prescription in naturalistic conditions. Family Practice, 2011, 28, 400-405.	0.8	5
172	Longâ€ŧerm risk of hip or forearm fractures in older occasional users of benzodiazepines. British Journal of Clinical Pharmacology, 2020, 86, 2155-2164.	1.1	5
173	Use of benzodiazepines non-compliant with guidelines in patients with psychiatric and non-psychiatric chronic disorders. General Hospital Psychiatry, 2020, 65, 21-27.	1.2	5
174	Pharmacoepidemiology of psychotropic drugs: examples of current research challenges on major public health issues. Epidemiologia E Psichiatria Sociale, 2009, 18, 107-13.	1.0	5
175	Delusional Mania: What Is a Mood-Incongruent Psychotic Feature?. Journal of Nervous and Mental Disease, 1993, 181, 517-518.	0.5	4
176	Is early adulthood a critical developmental stage for psychosis proneness? A survey of delusional ideation in normal subjects. Schizophrenia Research, 1998, 29, 24.	1.1	4
177	Editorial: Psychiatry in France. International Journal of Social Psychiatry, 2003, 49, 83-86.	1.6	4
178	Did the US boycott of French products spread to include scientific output?. BMJ: British Medical Journal, 2004, 329, 1430-1431.	2.4	4
179	Neurocognitive insight and executive functioning in schizophrenia. Cognitive Neuropsychiatry, 2015, 20, 64-71.	0.7	4
180	Hospitalisation sans consentementÂ: fondements éthiques, contraintes et justice procédurale. Annales Medico-Psychologiques, 2016, 174, 832-838.	0.2	4

#	Article	IF	CITATIONS
181	Functioning and cognitive characteristics of clozapine users referred to psychosocial rehabilitation centers: A REHABase cohort study. Psychiatry Research, 2019, 281, 112543.	1.7	4
182	Gender differences in metabolic monitoring of secondâ€generation antipsychotic prescription. Human Psychopharmacology, 2008, 23, 471-474.	0.7	3
183	Impact of prenatal exposure to diethylstilbestrol (DES) on psychological outcome: a national survey of DES daughters and unexposed controls. Archives of Women's Mental Health, 2017, 20, 389-395.	1.2	3
184	Antipsychotic prescribing in youths: A French community-based study from 2006 to 2013. European Psychiatry, 2015, 30, S9-S10.	0.1	2
185	Maternal post-natal depressive symptoms at 2 months: Effects of French antenatal preventive measures in the E.L.F.E. cohort. Journal of Affective Disorders, 2021, 293, 238-244.	2.0	2
186	Trauma and resistance to antipsychotic treatment in schizophrenia: A narrative review. Psychiatry Research, 2022, 309, 114392.	1.7	2
187	Does familiality predispose to both emergence and persistence of psychosis? A prospective study. Schizophrenia Research, 1996, 18, 113.	1.1	1
188	Winter birth excess in schizophrenics born in french urban areas. Schizophrenia Research, 1996, 18, 102.	1.1	1
189	Individual patient data metaanalysis of the association between schizophrenia and abnormalities of pregnancy and labour. Schizophrenia Research, 1997, 24, 250.	1.1	1
190	Increased occurrence of depression in psychosis-prone subjects. A follow-up study in primary care settings. Schizophrenia Research, 2000, 41, 76.	1.1	1
191	Frequency and hospitalisation-related costs of manic episodes in patients with bipolar I disorder in France. European Psychiatry, 2002, 17, 108.	0.1	1
192	Which cannabis users develop psychosis?., 2011,, 137-143.		1
193	Dépression maternelleÂ: facteurs de risque, conséquences sur le développement des enfants et interventions de prévention. European Psychiatry, 2015, 30, S33-S34.	0.1	1
194	Médicaments psychotropes chez l'enfant et l'adolescent. European Psychiatry, 2015, 30, S9-S9.	0.1	1
195	Safety of psychotropic medicines: contribution from observational evidence. Epidemiology and Psychiatric Sciences, 2018, 27, 531-536.	1.8	1
196	Clozapine and COVID-19: The authors respond. Journal of Psychiatry and Neuroscience, 2020, 45, E1-E2.	1.4	1
197	The association of clozapine and haematological malignancies needs to be replicated by other studies and more importantly by analyses of subsamples from VigiBase. Psychological Medicine, 2020, , 1-2.	2.7	1
198	Obstetric complications, maternal psychopathology, and the risk of psychosis., 2002, , 105-112.		1

#	Article	IF	CITATIONS
199	Schizophrenics with a family history of bipolar disorder. Possible involvement of obstetric complications. European Psychiatry, 1993, 8, 223-226.	0.1	0
200	Dr. Verdoux and Colleagues Reply. American Journal of Psychiatry, 1998, 155, 1626ah-1626.	4.0	0
201	Predictors and impact on outcome of medication compliance in first-admitted subjects with psychosis. Schizophrenia Research, 2000, 41, 223.	1.1	0
202	Neuropsychological function and duration of illness in psychotic and mood disorders. Schizophrenia Research, 2000, 41, 273.	1.1	0
203	S36.03 Delusions in the General Population. European Psychiatry, 2000, 15, 286s-286s.	0.1	0
204	Pathways to care in early psychosis. Schizophrenia Research, 2003, 60, 37.	1.1	0
205	Evidence that social environments modify the expression of psychosis vulnerability in daily life. Schizophrenia Research, 2003, 60, 53-54.	1.1	0
206	From conduct disorder to severe mental illness: a risky pathway. Psychological Medicine, 2008, 38, 927-928.	2.7	0
207	Reduced risk of hospitalisation with risperidone long-acting injectable. Results of the french cohort for the general study of schizophrenia (CGS). European Psychiatry, 2011, 26, 1487-1487.	0.1	0
208	P2-538 Using the CES-D scale in a large cohort and dealing with missing data: application to the French E3N cohort. Journal of Epidemiology and Community Health, 2011, 65, A369-A370.	2.0	0
209	Facteurs de vulnérabilité. , 2012, , 105-121.		0
210	Social inequalities in antidepressant treatment. European Psychiatry, 2013, 28, 75-75.	0.1	0
211	Impact de l'évaluation de la métacognition «Âon line» sur les performances cognitives auprès d' population non clinique. European Psychiatry, 2013, 28, 23-23.	une 0.1	0
212	1020 Psychotropic drug treatment of people with and without cancer in France: The VICAN study. European Journal of Cancer, 2015, 51, S151-S152.	1.3	0
213	Les facteurs associés à la dépression post-partum dans la cohorte Étude Longitudinale Française depuis l'Enfance (ELFE). European Psychiatry, 2015, 30, S34-S34.	0.1	0
214	The use of random-effects models to identify health care center-related characteristics modifying the effect of antipsychotic drugs. Clinical Epidemiology, 2017, Volume 9, 689-698.	1.5	0
215	Trajectories of Antipsychotic Drug Use Over 10 Years in a French Community-Based Sample of Persons Aged 50 and Older. American Journal of Geriatric Psychiatry, 2019, 27, 73-83.	0.6	0
216	Las mujeres con trastornos de ansiedad durante el embarazo corren mayor riesgo de sÃntomas depresivos postnatales intensos: Un estudio prospectivo de la cohorte MATQUID. European Psychiatry (Ed Española), 2005, 12, 207-211.	0.0	0

#	Article	IF	CITATIONS
217	Un estudio de los conocimientos de los médicos generales de los sÃntomas y la epidemiologÃa de la esquizofrenia. European Psychiatry (Ed Española), 2006, 13, 393-400.	0.0	0
218	Consumo de psicotr \tilde{A}^3 picos y riesgo de hospitalizaci \tilde{A}^3 n relacionado con el calor. European Psychiatry (Ed Espa $\tilde{A}\pm$ ola), 2007, 14, 408-412.	0.0	0
219	Comorbidity of bipolar disorder and bulimia nervosa. European Psychiatry, 1994, 9, 315-317.	0.1	O
220	Análisis de la variación estacional del nacimiento de los esquizofrénicos utilizando un estadÃstico del tipo Kolmogorov-Smirnov. European Psychiatry (Ed Española), 1997, 4, 452-458.	0.0	0
221	Actividades de investigación sobre esquizofrenia en 17 paÃses de habla no inglesa: un estudio de MEDLINE. European Psychiatry (Ed Española), 1998, 5, 116-118.	0.0	O
222	Predicción de la duración de la psicosis antes de la primera admisión. European Psychiatry (Ed) Tj ETQq0 0 0 0	rgBT Ove	lock 10 Tf 50
223	Prescription médicamenteuse en faveur de la réhabilitation. , 2018, , 273-284.		0
224	Dynamiques temporelles de remboursements de médicaments anxiolytiques chez des nouveaux consommateurs de 50 ans et plus. French Journal of Psychiatry, 2018, 1, S133-S134.	0.1	0